TRADING STATEMENT

In terms of paragraph 3.4(b)(i) of the Listings Requirements of the JSE Limited, listed companies are required to publish a trading statement as soon as they become reasonably certain that the financial results for the next period to be reported on will differ by more than 20% from those of the previous corresponding period.

The directors of Advanced Health hereby advise shareholders that, in respect of the unaudited consolidated interim results for the period ended 31 December 2019, the loss per share and headline loss per share are expected to be as follows:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Loss per share and headline loss per share (cents)</td>
<td>Expected increase of between 14% and 26%</td>
<td>Expected decrease of between 37% and 43%</td>
<td>Between 7.10 and 7.84 cents per share</td>
<td>Between 3.56 and 3.94 cents per share</td>
<td>6.21 cents per share</td>
</tr>
<tr>
<td>% range between</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note:

1. IFRS 16 Leases was adopted using the modified retrospective approach with the date of initial application being 1 July 2019. Comparative figures were not restated with the cumulative effect of initially applying the standard recognised at the date of initial application as an adjustment to opening accumulated loss. The adjustment to accumulated loss amounts to R17.2 million which relates to the reversal of the operating lease assets and liabilities and the deferred tax thereof recognised as at 30 June 2019.

Further explanations regarding the impact of the adoption of IFRS 16 Leases, will be disclosed in the Company’s interim results for the six months ended 31 December 2019, which are anticipated to be released on or about 27 February 2020.

The information in this trading statement has not been reviewed and reported on by the Company’s auditors.

Pretoria
20 February 2020

Designated Advisor
Grindrod Bank Limited